GSK, Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential to Activate the Immune System Even in ...
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...
An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...
GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
Shares of GSK PLC GSK dropped 1.38% to £16.10 Tuesday, on what proved to be an all-around favorable trading session for the ...
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback